Clinical Trial to Evaluate Short-term Efficacy of Palliative Methylphenidate in Asthenia in Advanced Cancer Patients
Double-blind, Placebo-controlled, Multicenter Randomized Clinical Trial to Evaluate Short-term Efficacy of Palliative Treatment With Methylphenidate in Asthenia in Advanced Cancer Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Clinica Universidad de Navarra
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Advanced cancer; including metastatic, locally advanced or relapsed not amenable for curative treatment.
- Mini.mental status examination results within normal limits.
- Informed consent.
- Estimated life expectancy of at least one month.
- Hemoglobin >= 9 g/dl.
- Asthenia >= 5 (0-10; numeric verbal scale).
Exclusion Criteria:
- History of psychosis.
- Structured suicidal ideation.
- Severe anxiety.
- Severe renal, hepatic or cardiac (arrythmia, hypertension, ischemic heart disease) failure.
- Simultaneous treatment with drugs that may interact with methylphenidate as: coumarinics, anticonvulsivants (phenobarbital, phenitoin, primidone), phenylbutazone, inhibitors of mono-amine-oxidase, guanethidine.
- History of glaucoma.
- Hyperthyroidism.
- History of hypersensibility to methylphenidate.
- Clinical suspicion of: infection, hypercalcemia, hypothyroidism or renal failure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: methylphenidate
methylphenidate (pill) p.o. 15 to 25 mg daily for six days
|
methylphenidate (pill) p.o. 15 to 25 mg daily for six days
|
|
PLACEBO_COMPARATOR: placebo
the same number of pills (p.o.) than methylphenidate for six days
|
placebo (pill) p.o.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intensity of asthenia assessed with the verbal numeric scale (VNS) included on the Edmonton Symptom Assessment System (ESAS)
Time Frame: After six days of therapy
|
We are looking for a difference between goups (methylphenidate versus placebo) of 1.5 (numeric rating scale: o to 10)
|
After six days of therapy
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intensity of asthenia assessed with the subscale for fatigue of the Functional Assessment of Cancer Therapy (FACT-F)
Time Frame: After six days of therapy
|
After six days of therapy
|
|
|
Intensity of asthenia assessed with the verbal numeric scale (VNS) included on the Edmonton Symptom Assessment System (ESAS) and the subscale for fatigue of the Functional Assessment of Cancer Therapy (FACT-F).
Time Frame: After three and six days of therapy
|
After three and six days of therapy
|
|
|
Intensity of other symptoms assessed with the Edmonton Symptom Assessment System (ESAS)
Time Frame: After three and six days of treatment
|
After three and six days of treatment
|
|
|
Number of participants with treatment-related adverse events and severity of these adverse events.
Time Frame: After three and six days of treatment
|
We will check for methylphenidate-related adverse events as: restlessness, hyperactivity, hyporexia, nausea and vomiting, dry mouth, palpitations, sleep insomnia, cephalea, muscle cramps, tics, and any other adverse event that could be treatment-related according to investigator.
We will include the severity of the adverse event (mild, moderate, or severe), the presumed relationship with treatment, the measured required to treat it, and the final outcome.
|
After three and six days of treatment
|
|
Cognitive level.
Time Frame: After three and six days of treatment
|
We use a specific questionnaire.
In order to facilitate its use in fatigued patients it is designed with a limited number of items selected from three validated tools as MMSE, 3MS, and RBANS
|
After three and six days of treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Carlos Centeno Cortes, MD, Phd, Clinica Universidad de Navarra
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- METILAS
- 2008-002171-27 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.